

CURRICULUM VITAE

Ronald Prussick, M.D., F.R.C.P.(C)

Board Certified in Dermatology

Washington Dermatology Center

6163 Executive Blvd

Rockville, MD. 20852

tel: (301) 984-3000

ACADEMIC APPOINTMENTS

Assistant Clinical Professor of Dermatology, George Washington University, Washington, D.C.

Staff Physician 1992-1995, Sunnybrook Medical Center, University of Toronto, Ontario

Clinical Instructor 1992-1995, Dermatology & Pharmacology, University of Toronto

EDUCATION

- 1991-92 Fellowship in Dermatological Immunology
National Cancer Institute, National Institutes of Health (NIH)
- 1991 Certification - American Board of Dermatology
- 1991 Fellow of the Royal College of Physicians & Surgeons
- 1988-91 Chief Resident, Dermatology
University of Toronto, Ontario
- 1990 Oxford Summer School on Wound Healing, England
- 1990 Contact Dermatitis, Stanford University & UC California San Francisco
- 1990 Psoriasis Education and Research Centre, Univ. of Toronto
- 1987-88 Comprehensive Internship in Internal Medicine, Univ. of Toronto
- 1983-87 McGill University School of Medicine, Montreal, Canada
- 1980-83 McGill University, B.Sc., Great Distinction, Major in Biology & Genetics

MEMBERSHIP AND COMMITTEES

2015-present	Medical Scientific Advisory Board. Immunotec, Inc.
2014-present	NPF: Washington, DC, Community Division Medical Member
2014-present	NPF: Seal of Recognition- Expert Panel Member
2012-2018	Medical Board Member: National Psoriasis Foundation (NPF)
2012-present	Psoriasis Expert Resource Group (PERG) member: AAD
2010-present	PsoriasisNet Work group: American Academy of Dermatology (AAD)
2010-2011	Health Volunteers Overseas
2006-present	National Psoriasis Foundation President's Council
1997-2003	Chairman, Adverse Drug Reactions Committee, Suburban Hosp.
1997-2003	Pharmacy & Therapeutics Committee, Suburban Hosp.
1996-1998	Community Affairs Committee, MCMS
1995-present	Montgomery County Medical Society (MCMS)
1995-present	MedChi Maryland State Medical Society
1995-present	American Society for Laser Medicine & Surgery
1993-present	International Society for Dermatologic Surgery
1996-1998	Third Party Payer Committee, MCMS
1992-1995	Executive Council Toronto Dermatological Society
1991-present	Fellow of the American Academy of Dermatology
1991-present	Canadian Dermatology Association
1988-present	The Ontario College of Physicians & Surgeons
1985-86	McGill Senate Committee on Disabled Students
1984-86	McGill Health Services Advisory Board
1984	Chairman, McGill Medical Blood Drive
1982-83	Committee on Faculty, McGill University
1982-83	Committee on Student Standing, McGill University
1982	Chairman, McGill University Blood Drive

EDITOR / REVIEWER - MEDICAL JOURNALS & INDUSTRY

2017-	Psoriasis Advance Magazine- Medical Editor
2011-present	Associate Journal Editor: <i>Journal of Psoriasis and Psoriatic Arthritis (JPPA)</i>
2004	Amgen - Dermatology Managed Care Panel, Washington, D.C.
2000	Alwyn, Inc. -Medical Advisor for TV spot: Lupicare™ for Psoriasis
1993-present	<i>Journal of American Academy of Dermatology (JAAD)</i>

TEACHING ACTIVITIES

- 2009 Allergan: Juvederm™ Physician Trainer
Medicis: Dysport™ and Restylane™ Physician Trainer
- 1995-present George Washington University, Medical Student/Dermatology Resident Teaching
- 1993-1995 University of Toronto Weekly Dermatology Teaching Clinics
Year III Medical Student Teaching: Group Leader, Hospital Clinics
Dermatology Residents: Group Leader, Journal Club
Examiner: Dermatology Residents' Practice Examination

SKIN CARE DEVELOPMENT

2016- Creator of ELASENSE anti-aging skin care line with SynerG-4 sold worldwide.
Immunotec, Inc.

PUBLICATIONS

I. Peer Review Publications

Ford A, Siegel M, Bagel J, Cordero KM, Garg A, Gottlieb A, Green LJ, Gudjonsson JE, Koo J, Lebwohl M, Liao W, Mandelin AM, Markenson JA, Mehta N, Merola JF, Prussick R, et al. Dietary Recommendations for Adults with Psoriasis or Psoriatic Arthritis from the Medical Board of the National Psoriasis Foundation: A Systematic Review. *JAMA Dermatol.* 2018;154(8):934-950.

Prussick R, Miele L. Nonalcoholic Fatty Liver Disease in Patients with Psoriasis: A Consequence of Systemic Inflammatory Burden? *Br J Dermatol.* 2018 July; 179:16-29.

Prussick R, Wu JJ, Armstrong AW, Siegel MP, Van Voorhees AS. Psoriasis in Solid Organ Transplant Patients: Best Practice Recommendations from the Medical Board of the National Psoriasis Foundation. *J Dermatol Treat.* 2018 Jun; 29(4):329-333.

Dey AK, Joshi AA, Chaturvedi A, Lerman JB, Aberra TM, Rodante JA, Teague HL, Harrington CL, Rivers JP, Chung JH, Kabbany MT, Natarajan B, Silverman JL, Ng Q, Sanda GE, Sorokin AV, Baumer Y, Gerson E, Prussick RB, Ehrlich A, Green LJ, Lockshin BN, Ahlman MA, Playford MP, Gelfand JM, Mehta NN. Association Between Skin and Aortic Vascular Inflammation in Patients with Psoriasis. A Case-Cohort Study Using Positron Emission Tomography/ Computed Tomography. *JAMA Cardiol.* 2017.Sep 1;2(9):1013-1018.

Armstrong AW, Siegel MP, Bagel J, Boh EE, Buell M, Cooper KD, Callis Duffin K, Eichenfield LF, Garg A, Gelfand JM, Gottlieb AB, Koo JY, Korman NJ, Gerald G Krueger, Lebwohl MG, Leonardi CL, Mandelin AM, Menter MA, Merola JF, Pariser DM, Prussick RB, Ryan C, Shah KN, Weinberg JM, Williams MJ, Wu JJ, Yamauchi PS, Van Voorhees AS. From the Medical Board of the National Psoriasis Foundation. Treatment Targets for Plaque Psoriasis. *J Amer Acad Dermatol.* 2017;76(2):290-298.

Desai SR, Feldman S, Prussick R, Weiss S. Optimizing Adherence in Psoriasis: Pearls from the Front Line. *Practical Dermatology.* 2017;14(1):42-43.

Prussick L, Jimenez E, Nussbaum D, Prussick R. Psoriasis and Psychological Comorbidities. *J Psoriasis and Psoriatic Arthritis.* 2016;1(2):80-85.

Prussick R, Unnebrink K, Valdecantos WC. Efficacy of Adalimumab Compared with Methotrexate or Placebo Stratified by Baseline BMI in a Randomized Placebo-Controlled Trial in Patients with Psoriasis. *J Drugs Dermatol.* 2015;14 (7):611-615.

Naik H, Natarajan B, Stansky E, Ahlman M, Teague H, Salahuddin T, Ng Q, Krishnamoorthy P, Dave J, Rose S, Doveikis J, Playford M, Prussick R, Ehrlich A, Kaplan M, Lockshin B, Gelfand J, Mehta N. Severity of Psoriasis Associates with Aortic Vascular Inflammation Detected by FDG PET/CT and Neutrophil Activation in a Prospective Observational Study. *Arterioscler Thromb Vasc Biol.* 2015 Dec;35(12):2667-76.

Prussick R, Prussick L, Nussbaum D. Nonalcoholic Fatty Liver Disease and Psoriasis: What a Dermatologist Needs to Know. *J Clin Aesthet Dermatol.* 2015;8(3): 43-45.

Prussick L, Prussick R. Vitamin D and Psoriasis. *Practical Dermatol.* 2013;10 (11):27-30.

Prussick R, Prussick L, Gutman J. Psoriasis Improvement in Patients using Glutathione-Enhancing, Non-Denatured Whey Protein Isolate: A pilot study. J Clin Aesthet Dermatol. 2013;6(10):23-26.

Prussick R, Rengifo-Pardo M. Myelodysplastic syndrome related to the use of etanercept in a patient with psoriasis. Psoriasis Forum. 2013;19 (1):56-57.

Prussick R, Prussick L. Biologics for Psoriasis 2013: Do we use them enough? Practical Dermatol. 2013;10(2): 32-34.

Prussick L, Prussick R. Maintenance ultraviolet therapy in Psoriasis: Is it Necessary? Psoriasis Forum. 2012; 18(3):147-148.

Prussick R. Biologic therapies for Psoriasis: Do we use them enough? Expert Rev Dermatol. 2010; 5(5):497-499.

Prussick R. Urticaria: An Approach to the Diagnosis and Treatment of Hives. Trauma. 1998;40(4):85-90.

Prussick R. Adverse Cutaneous Reactions to Drugs. Trauma. 1998;39(6)61-66.

Gupta AK, Sibbald RG, Lynde CW, Hull PR, Prussick R, Shear NH, De Donker P, Daniel R, Elewski BE. Onychomycosis in children: Prevalence and treatment strategies. J Am Acad Dermatol. 1997;36:395-402.

Gupta AK, Prussick R. and Sauder DN. Biological Response Modifiers. McDonald, CJ ed. Immunodulatory and Cytotoxic Agents in Dermatology. New York, N.Y.: Marcel-Dekker, Inc. 1997;71-123.

Prussick R, Wilson WH, Horn TD, and Turner ML. A Characteristic eruption associated with ifosfamide, carboplatin, and etoposide chemotherapy after pretreatment with recombinant interleukin-1a. J Am Acad Dermatol. 1996;35:705-709.

Prussick R. Adverse Cutaneous Reactions to Chemotherapeutic Agents and Cytokine Therapy. Semin Cutaneous Med and Surg. 1996;15(4):267-276.

Prussick R, Shear NH. Dapsone Hypersensitivity Syndrome. J Am Acad Dermatol. 1996;35:346-349.

Gupta AK, Turnbull DH, Foster FS, Harasiewicz KA, Shum DT, Prussick R, Wateel GN, Hurst LN, Sauder DN. High frequency 40-MHz ultrasound. A possible noninvasive method for the assessment of the boundary of basal cell carcinomas. Dermatol Surg. 1996; 22(2);131-6.

Shear NH and Prussick R. Drug Eruptions and Skin Manifestations of Immune Suppression. In Dover, J.S. ed. Cutaneous Medicine and Surgery: Self-Assessment and Review. Philadelphia, PA: W.B. Saunders Co. 1995.

Gupta AK, Prussick R, Sibbald G. and Knowles S.R. Terbinafine in the Treatment of Majocchi's Granuloma. Int J Dermatol. 1995;34(7):150.

Knowles SR, Prussick R. and Shear NH. Unexpected skin reactions to systemic drugs. Med North Amer. 1995;18(3):273-277.

Prussick R. Adverse skin reactions to chemotherapeutic agents. Contemp Dermatol. 1994;3:7-12.

Prussick R, Knowles S. and Shear N.H. Cutaneous Drug Reactions. Curr Probl Dermatol. 1994;V:181-124.

Prussick R, Plott TR and Stanley JR. Recurrence of Pemphigus Vulgaris Associated with IL-2 Therapy. Arch Dermatol. 1994;130:890-893.

Karpati S., Amagai M, Prussick R and Stanley, J.R. Pemphigus Vulgaris Antigen is a Desmosomal Desmoglein. Dermatol. 1994;189 (suppl 1):24-26.

Prussick R, Gupta AK, Assaad DM, Hanna WM and Sauder, D.N. Epidermolysis Bullosa Acquisita with Features of Bullous Lupus Erythematosus. Int J Dermatol. 1994;33:192-195.

Karpati S, Amagai M, Prussick R, Cehrs K. and Stanley JR. Pemphigus Vulgaris Antigen, a Desmoglein Type of Cadherin, is Localized within Keratinocyte Desmosomes. J Cell Biol. 1993;122:409-415.

Prussick R, Thibault A. and Turner ML. Recall of Cutaneous Toxicity from 5-Fluorouracil. Arch Dermatol. 1993;129:644-645.

Amagai M, Karpati S, Prussick R, Klaus-Kovtun V and Stanley J.R. Autoantibodies are Pathogenic in Pemphigus Vulgaris. J Clin Invest. 1992;90:919-926.

Prussick R, Ali MAM, Rosenthal, D. and Guyatt, G. The Protective Effect of Vitamin E on the Hemolysis associated with Dapsone Treatment in patients with Dermatitis Herpetiformis. Arch Dermatol. 1992;128:210-213.

Prussick R and Sauder DN. Polymyositis: A Manifestation of Chronic Graft Versus Host Disease. J Am Acad Dermatol. 1991;24:652-653.

Patel A, Prussick R and Sauder DN. Leukocytoclastic Vasculitis associated with Streptokinase. J Am Acad Dermatol. 1991;24:652-653.

Brown GG, Bell G. and Prussick R. Variation in Animal Mitochondrial Genes and Gene Products. Endocytobiology. Walter de Gruyter & Co.: Berlin-New York. 1983;II(246).

II. Abstracts

Amagai M, Karpati S, Prussick R, Klaus-Kovtun V and Stanley JR. Autoantibodies Against the Cadherin-like Homophilic Binding Region of Pemphigus Vulgaris Antigen Cause Acantholysis. J Invest Dermatol. 1992;98:566.

Prussick R, Ali MAM and Rosenthal D. Protection from Oxidative Damage by Oral Vitamin E and Vitamin C in patients on long term Dapsone Therapy. Can Dermatol Assoc J. 1990;(4)3.

Brown GG and Prussick R. Deletion and Insertion Events in Rat Mitochondrial DNA. Genetics. 1983;104(1:9).

III. Book Reviews

Adverse Cutaneous Reactions to Medications. By Sanford M. Goldstein MD and Bruce U. Wintroub MD, Baltimore, 1996, Williams & Wilkins, 160 pages. J Am Acad Dermatol. 1997;37:29.

IV. Posters

Patients with Psoriasis Treated with Brodalumab: A Pooled Post Hoc Analysis of a Marker of Liver Inflammation in Individuals with Potential Indicators of Early Nonalcoholic Fatty Liver Disease (NAFLD). Prussick R, Lebwohl M, Harris S, Vittitow J, Heimanson Z, Jacobson A, Israel RJ. Winter Clinical Dermatology Conference, Hawaii, 2019.

Efficacy of Adalimumab Compared With Placebo Stratified by Baseline Disease Severity in Moderate to Severe Psoriasis from the CHAMPION and REVEAL Studies. Armstrong A, Lambert J, Prussick R, Geng Z, Reyes Servin O. AAD Annual Meeting, San Diego, CA. February 2018.

Effect of Adalimumab Treatment on Body Weight and Metabolic Parameters: Integrated Analysis from Phase 2/3 Clinical Trials in Patients with Moderate to Severe Psoriasis. Prussick R, Gu Y, Reyes Servin O. EADV Congress, Vienna, Austria. September 2016 and AAD Annual Meeting, Orlando, FL. March 2017.

Improvement in Psoriasis Skin Disease Severity is Associated with Improvement in Aortic Vascular Inflammation by FDG PET/CT. Day A, Lerman J, Abera T, Joshi A, Rodante J, Kabbany M, Silverman J, Dahlya A, Natarajan B, Teague H, Salahuddin T, Ng Q, Playford M, Gerson E, Prussick R, Ehrlich A, Lockshin B, Ahlman M, Gelfand J, Mehta N. EADV Congress, Vienna, Austria. September 2016.

Efficacy of Adalimumab Compared with Methotrexate or Placebo Stratified by Baseline BMI in a Randomized Placebo-Controlled Trial. Ronald Prussick MD, Kristina Unnebrink PhD, Eric Gorayeb MD. Fall Clinical Dermatology Meeting, Las Vegas, Nevada. October 2014 and AAD Annual Meeting, San Francisco, CA. March 2015.

ACADEMIC LECTURES/FORUMS/ROUND TABLES/WEBINARS

“Tremfya Experience”. Psoriasis Ad Board sponsored by Janssen Immunology. San Juan, Puerto Rico. December 2018.

“Diet, Fatty Liver and Psoriasis”. Toronto Psoriasis Seminar (ToPS). Toronto, Canada. November 2018.

“The Role of Diet in Inflammatory Skin Conditions”. Robert Lester Postgraduate Seminar. Toronto, Canada. November 2018.

“Approaches to Managing Complex Psoriasis Cases” and “Comorbidities in Psoriasis”. NPF symposium in the 42nd Annual Southeastern Consortium for Dermatology. Charleston, SC. November 2018.

“Comorbidities in Psoriasis: What you need to know”. Webinar sponsored by the National Psoriasis Foundation. September 2018.

“Psoriasis 101: An Overview”. Grand Rounds Internal Medicine. Grady Hospital, Atlanta, GA. Sponsored by the National Psoriasis Foundation. March 2018.

“Comorbidities in Psoriasis: What a Dermatologist Needs to Know”. Focus Session Director. AAD Annual Meeting. San Diego, CA. Feb 2018.

“Comorbidities in Psoriasis”. Early Careers Physician Symposium. Sponsored by the National Psoriasis Foundation. Hershey, Pa. October 2017.

“Every Patient Every Visit: Looking Beyond the Skin for Patients with Psoriatic Arthritis”. Speaker Training for AbbVie Immunology. Dallas, TX. October 2017.

“A Milestone in the Treatment of Moderate to Severe Hidradenitis Suppurativa”. Product Theater, 94th Annual Atlantic Dermatology Conference. Sponsored by AbbVie Immunology. Toronto, Canada. May 2017.

“Comorbidities in Psoriasis: What a Dermatologist Needs to Know”. Focus Session Director. AAD Annual Meeting. Orlando, Fl. March 2017.

“Learning the Links: Discussing Comorbidities Associated With Plaque Psoriasis and Hidradenitis Suppurativa”. AbbVie Speaker Training. Dallas, TX. December 2016.

“Krazy Kodachromes” for Derm In-Review Online. Educational resource to prepare for Board Certification Exams. September 2016.

“Alternative and Complementary Treatments in Dermatology”. Guest Speaker at the 38th Annual Bob Lester Post-Graduate Dermatology Seminar. Toronto, Canada. November 2016.

“Update on Comorbidities in Psoriatic Disease”. Guest Faculty at the 12th Annual Toronto Psoriasis Seminar. Toronto, Canada. November 2016.

“Alternative and Complementary Treatments in Psoriasis”. AAD Summer Meeting. Boston, MA. July 2016.

“A Milestone in the Treatment of Moderate to Severe Hidradenitis Suppurativa”. The National Academy of Dermatology Nurse Practitioners Annual Conference”. Sponsored by AbbVie Immunology. Clearwater, FL. May 2016.

“Comorbidities in Psoriasis: What a Dermatologist Needs to Know”. Focus Session Director. AAD Annual Meeting. Washington, DC. March 2016.

“A Legacy in Dermatology. A Commitment to Your Patients”. Sponsored by AbbVie Immunology. Jacksonville, FL. February 2016.

“Ustekinumab Safety Data” and “Comorbidities in Psoriasis”. Annual Speaker Training. Sponsored by Janssen Biotech. Denver, CO. January 2016.

“Alternative Treatments in Psoriasis” Guest Faculty at the 11th Annual Toronto Psoriasis Seminar. Toronto, Canada. September 2015.

“Comorbidities in Psoriatic Diseases”. Guest Speaker at the Canadian Dermatology and Rheumatology Comorbidities Initiative in Psoriatic Disease. Toronto, ON, Canada, September 2015.

Webinar: “ICD-10-CM and Psoriasis Coding: What you need to know.” Ronald Prussick, MD, FRCP(C), FAAD and Faith McNicholas. Sponsored by The National Psoriasis Foundation. September 2015.

“Partners in Care: Collaborating to Advance the Care for Patients with Psoriatic Arthritis”. Dermatology and Rheumatology dual slide deck. National Speaker Training webcast with Dr Phil Mease. Sponsored by AbbVie Immunology. August 2015.

“Understanding Psoriatic Disease Comorbidities”. National NPF Volunteer Conference. Sponsored by the National Psoriasis Foundation. San Francisco, CA. July 2015.

“Roundtable Discussions in Dermatology: Biologic Therapy in Adults with Moderate to Severe Plaque Psoriasis or Active Psoriatic Arthritis”. Sponsored by Janssen Biotech. New York, New York. May 2015.

“An Oral PDE4 inhibitor for the Treatment of Moderate to Severe Plaque Psoriasis” Sponsored by Celgene. White Plains, MD. April 2015.

“Comorbidities in Psoriasis: What a Dermatologist Needs to Know”. Focus Session Director. AAD Annual Meeting. San Francisco, CA, March 2015.

“Efficacy of Adalimumab Compared With Methotrexate or Placebo Stratified by Baseline BMI in a Randomized, Placebo-Controlled Trial. Poster Presentation. AAD Annual Meeting. San Francisco, CA, March 2015.

“Panel Discussion on Frequently Asked Questions: Psoriasis Comorbidities”. Stelara National Faculty Training. Sponsored by Janssen Biotech, Inc. Atlanta, GA, January 2015.

“Plaque Psoriasis: Clearing Skin, Challenging Expectations”. Sponsored by AbbVie Immunology. Gainesville, FL, January 2015.

“Clinical Casebook in Dermatology: Biologic Therapy in Moderate to Severe Plaque Psoriasis and Active Psoriatic Arthritis”. Sponsored by Janssen Immunology, Inc, Philadelphia, PA, December 2014.

“Achieving Results: Clinical Trial Experience Translated into Clinical Practice”. Sponsored by AbbVie Immunology, Atlanta, GA, October 2014.

“Psoriatic Arthritis: Co-Management”. Sponsored by AbbVie Immunology. Falls Church, VA, October 2014.

National Psoriasis Foundation Corporate Roundtable at the AAD- Physicians Panel. Denver, CO, March 2014.

Guest Dermatologist for Video on “Psoriatic Disease and Humira”. Made for *Healthcasts.com* and *The Clinical Advisor.com*. Denver, CO, March 2014.

“Considerations for Making Therapeutic Decisions in Patients with Psoriasis”. Sponsored by Janssen Biotech, Inc, Charlottesville, VA, October 2013.

“Safety Profile: Putting into perspective”. Sponsored by Abbvie Immunology, Pittsburgh, PA, October 2013.

“Current Psoriasis Treatments: How to Choose”, Lecture for WHC/Georgetown Dermatology Residents, Washington Hospital Center, Washington, DC, September 2013.

“Safety Profile: Putting it into Perspective”, Sponsored by Abbvie Immunology, Honolulu, HI, July 2013.

“Long-Term Treatment and Retreatment of Moderate to Severe Chronic Plaque Psoriasis”. Sponsored by Abbvie Immunology, Orlando, FL, May 2013.

“Comorbidities in Patients with Psoriasis”. Atlantic Dermatological Conference, Washington DC, April 2013.

“Long-Term Treatment and Retreatment of Moderate to Severe Chronic Plaque Psoriasis”. Sponsored by Abbott Immunology, Charlotte, NC, November 2012.

“Review of a Multicenter, Double-Blind Study to Treat Acne Vulgaris”. Sponsored by L’Oreal USA, Inc., Bethesda, MD, November 2012.

“Treatment Strategies for Psoriatic Disease”. Sponsored by Abbott Immunology, Annapolis, MD, October 2012.

“Picato Gel. A New Treatment for Actinic Keratoses”. Sponsored by LEO Pharma Inc. Chevy Chase, MD, October 2012.

“Safety Data for Humira in Moderate to Severe Plaque Psoriasis”. Sponsored by Abbott Immunology, Atlanta, GA, July 2012.

“Dysport and Restylane training”. Sponsored by Medicis Inc., Bethesda, MD, June 2012.

“A Global Clinical Trial Safety Review”. Sponsored by Abbott Immunology, Charlottesville, VA, May 2012.

“Treatment Strategies for Psoriatic Diseases”. Sponsored by Abbott Immunology, Baltimore, MD, May 2012.

“Long term Treatment and Retreatment of Moderate to Severe Chronic Plaque Psoriasis”. Sponsored by Abbott Immunology, Atlanta, GA, February 2012.

“Managing Moderate to Severe Psoriasis in Patients Ready for a Biologic”. Sponsored by Abbott Immunology, Lynchburg, VA, February 2012.

“Psoriasis: A Closer Look. A Program for Primary Care Providers”. Sponsored by Abbott Immunology, Rockville, MD, October 2011.

“A Global Trial Safety Review of Adalimumab for Gastroenterologists”. Sponsored by Abbott Immunology, National Harbor, MD, October 2011.

“A Global Clinical Trial Safety Review”. Sponsored by Abbott Immunology, Richmond, VA, June 2011.

“Long Term Treatment and Retreatment of Moderate to Severe Chronic Plaque Psoriasis”. Teleconference to 5 cities in USA, Sponsored by Abbott Immunology, North Bethesda, May 2011.

“Biologic Drugs for Psoriasis- Do We Use Them Enough?” Forum Director. AAD Annual Meeting, New Orleans, LA, February 2011.

“Comorbidities Associated With Psoriasis”, Hospital Mexico, San Jose, Costa Rica, August 2010.

“Adverse Drug Reactions of the Skin” San Jose Dermatology Meeting, San Jose, Costa Rica, August 2010.

“Treatment of Psoriatic Diseases: A Clinical Trial Review”. Sponsored by Abbott Immunology, Philadelphia, PA, July 2010.

“Biologic Drugs for Psoriasis-Do We Use Them Enough?”. Forum Director, AAD Annual Meeting, Miami, FL, March 2010.

“Review of Botulinum Toxin Choices for Cosmetic Use”. Dinner Program Sponsored by Medicis Inc., Miami, FL, March 2010.

“Biologic Treatments for Psoriasis- What Pharmacists Need To Know”. Sponsored by Abbott Immunology, Bethesda, MD, December 2009.

“Treatment Options for Actinic Keratoses”. Sponsored by Pharmaderm. Tysons Corner, VA, September 2009.

“Psoriasis Case Review”. Sponsored by Abbott Immunology, Chevy Chase, MD, September 2009.

“Biologic Drugs for Psoriasis - Do We Use Them Enough?”. Forum Director, AAD Annual Meeting, San Francisco, CA, March 2009.

“Psoriasis and Psoriatic Arthritis 2009”. Scientific Congress Update, CME Program for Primary Care. San Francisco, CA, March 2009.

“Adverse Cutaneous Reactions to Drugs”. SDPA Annual Meeting, Tampa, FL, November 2008.

“Unveiling Humira for Psoriasis”. Regional Guest Speaker, Abbott Immunology, Baltimore/Washington, DC, Baltimore, MD. February 2008.

“Review of Biologic Agents to Treat Moderate to Severe Psoriasis”. Dermatology Residents Lecture: Washington, D.C., Sponsored by Abbott Immunology, February 2008.

“Review of New Biologic Treatment for Psoriasis”. Thomas Jefferson University, Department of Dermatology, Philadelphia, PA., Sponsored by Abbott Immunology, February 2008

“Update on Psoriasis Therapies”. Hahnemann University, Drexel College of Medicine, Department of Dermatology Grand Rounds, Philadelphia, PA. Sponsored by Abbott Immunology, February 2008.

“Psoriasis as a Systemic Inflammatory Disease”. Suburban Hospital Medical Grand Rounds, Bethesda, MD, November 2007.

“Psoriasis: Topical Strategies for Treating Psoriasis”. Ellicott City, MD. Sponsored by Warner Chilcott, Inc. March 2007.

“Review of Biologic Treatments in Psoriasis”. Duke University, Department of Dermatology, Durham, NC, sponsored by Abbott Immunology, April 2006.

“Adverse Cutaneous Reactions to Drugs”. Holy Cross Hospital Continuing Medical Education Lecture, Silver Spring, MD, Jan 1997.

“An Approach to Hives”. Holy Cross Hospital Grand Medical Rounds, Silver Spring, MD, Nov. 1996

“Chronic Urticaria”. Bethesda, MD, sponsored by Pfizer Inc., Oct 1996.

“Approach to Dermatology Patient Consultations”. Dermatology Teaching Rounds, National Naval Medical Centre, Bethesda, MD, June 1996.

“Hypersensitivity Drug Reactions”. Grand Medical Rounds, Suburban Hospital, Bethesda, MD, May 1996.

“Approach to Adverse Drug Reactions”. Grand Medical Rounds, Shady Grove Adventist Hospital, Rockville, MD, Mar. 1996.

“Adverse Drug Reaction Forum”. American Academy of Dermatology Annual Meeting, Washington, DC, Feb. 1996.

“Hypersensitivity Drug Reactions”. Walter Reed Hospital Teaching Lectures, Washington, DC, Oct. 1995.

“Antimicrobial Adverse Drug Reactions”. Sponsored by the Peterborough Medical Education Association Grand Rounds, in conjunction with Eli Lilly Canada Inc., Mar. 1995.

“Adverse Drug Reaction Forum”. AAD Annual Meeting, New Orleans, Feb. 1995.

“Macrolide Antibiotics”. Frontiers in Dermatology, Montreal, Quebec, Dec. 1994.

“Dapsone Hypersensitivity Syndrome”. Medical Grand Rounds, Sunnybrook Health Science Centre, Toronto, Ontario, Nov. 1994.

“Adverse Drug Reactions to Antimicrobial Therapy (A Review & Update)”. Sponsored by the Continuing Medical Education Association for Pediatricians of Waterloo, Ontario in conjunction with Eli Lilly Canada Inc., Oct. 1994.

“Adverse Reactions to Oral Antibiotics”. Sunnybrook Health Science Centre, Department of Family & Community Medicine, Toronto, Ontario, June 1994.

“Cutaneous Reactions to Chemotherapeutic Agents”. Dermatology Grand Rounds, Sunnybrook Health Science Centre, Toronto, Ontario, May 1994.

“Drug Reactions Commonly Seen in Internal Medicine”. Medical Core Lecture, Department of Medicine, Sunnybrook Health Science Centre, Toronto, Ontario, March 1994.

“A Review of Drug Eruptions”, sponsored by The Continuing Medical Education Association of Newmarket, Ontario. Sponsored by Eli Lilly Canada Inc., Feb. 1994

“Drug Eruptions - The Ultimate Test”, Medical Grand Rounds, Sunnybrook Health Science Centre, Toronto, Ontario, Jan. 1994.

“Adverse Drug Reaction Forum”. AAD Annual Meeting, San Francisco, Dec. 1993.

“Adverse Cutaneous Reactions to Cytokines & Chemotherapeutic Agents”, Oncology Grand Rounds, The Bayview Regional Cancer Centre, Toronto, Ontario, Nov. 1993.

“Infestations of the Skin”, Medical Grand Rounds, Peel Memorial Hospital, Brampton, Ontario, May 1993.

“Vascular Lesions in Childhood”, Pediatric Grand Rounds, North York General Hospital, Willowdale, Ontario, Feb. 1993.

“Pregnancy Eruptions”, Continuing Medical Education Symposium on Treatment of Common Dermatological Problems For the Family Practitioner, University of Toronto, Jan. 1993.

“Adverse Drug Reaction Forum”, AAD Annual Meeting, San Francisco, Dec. 1992.

“Vascular Lesions in Childhood”, Walter Reed Hospital Teaching Lectures, Washington, D.C. Sept. 1992.

“The Protective Effect of Vitamin E on the Hemolysis associated with Dapsone Treatment in Patients with Dermatitis Herpetiformis”, AAD Annual Meeting, Residents and Fellows Symposium, December 1990 (Atlanta) and the John Cole Memorial Residents Competition (Toronto), Feb. 1991.

“The Pustular Dermatoses in Pregnancy”, AAD Annual Meeting, December 1990 (Atlanta) & the John Cole Memorial Residents Competition (Toronto), Feb. 1990.

PUBLIC/PREVENTATIVE MEDICINE – LECTURES, INTERVIEWS & ARTICLES

“Treat To Target Guidelines for Psoriasis”. National Psoriasis Foundation Regional Volunteer Conference, October 2018, Alexandria, VA.

“If I’m clear why do I need to continue my treatment” and “Treatment side-effects what should I expect”, Podcasts for the National Psoriasis Foundation. October 2018.

“Psoriasis Comorbidities: Updates”. Interviews on Dermtube. March 2015, 2016 and 2018.

“Be Joint Smart”. Webinar on the benefits of early diagnosis, treatment and life style changes that can help with psoriatic arthritis. Given with Dr. Evan Siegel, Rheumatologist. Sponsored by the National Psoriasis Foundation. November 2017.

“More Than Skin Deep: Targets, Treatments & What it Means for You”. Bethesda, MD, Sponsored by the National Psoriasis Foundation. June 2017.

“Nail Psoriasis Patient Education Webinar”. Sponsored by the National Psoriasis Foundation. June 2017.

“Eczema prevention: Avoid the triggers”. WebMD video interview. July 2016.

“ELLASENSE- A novel anti-aging skin care line with SynerG-4”. Presented at the Immunotec Annual Conference. Las Vegas, Nevada. February 2016.

“More Than Skin Deep: Triggers, Treatments and You”. Sponsored by the National Psoriasis Foundation. Bethesda, MD. June 2015.

*“Ronald B. Prussick, MD: Interviewed on the topic of Communication in Patients with Psoriasis” in the Physician Focus Section. **Practical Dermatology**. 2014;11(10):82.*

*“Psoriasis Treatments: How Biologics Work”. **Everyday Health.com**. December 2013.*

“Be Joint Smart”, Outreach program co-sponsored by the National Psoriasis and Arthritis Foundations. Shady Grove Adventist Hospital, Rockville, MD, October 2012.

*“Melanoma Prevention and Awareness”, **Healthcentral.com**, June 2012.*

*“Psoriasis Triggers and Management”, **Healthcentral.com**. October 2011.*

“Psoriasis: More Than Skin Deep” Sponsored by the National Psoriasis Foundation. Marriott Hotel, Washington, DC, July 2011.

“If I had Severe Psoriasis and my Doctor Recommended Biologic Drugs“, www.medlineplus.gov and www.insidermedicine.com . March 2009.

“Acne Treatment”, FOX 5 News Medical Report, February 2007.

“Excimer Laser for Psoriasis”, NBC News Medical Report, May 2006.

“Skin Cancer: Detection, Prevention & Treatment”, Potomac Rotary Club, MD, Mar. 1997.

“Aging Skin”, Potomac Seniors Club, Potomac MD, Feb. 1997.

“Skin Cancer: Detection, Prevention & Treatment”, Public Lecture, Maplewood Senior Center, Bethesda, MD, Feb. 1997.

“Skin Care: Protection & Treatment”, Daytime Report: News Channel 8, Virginia, Jan. 1997.

“Skin Cancer: Detection, Prevention & Treatment”, Public Lecture, Ring House, Rockville, MD, Dec. 1996.

“Skin Cancer: Detection & Prevention”, Magruder High School, Montgomery County Public Schools Connection Resource Bank, Oct. 1996.

“Skin Cancer: Detection, Prevention & Treatment”, Public Lecture, Holiday Park Multiservice Senior Center, Wheaton, MD, Sept. 1996.

“Skin Care”, Suburban Hospital Pavillion, Bethesda, MD, July 1996.

“Fry Now, Pay Later”, article published in Women Today, Rockville, MD, June 1996.

“Skin Cancer Detection & Prevention”, Public Lecture, OASIS (Older Adult Service & Information System) Chevy Chase, MD, May 1996.

“The Treatment of Acne Scarring”, Montgomery Gazette, March 1996.

“Laser Treatment for the Skin”, Public Lecture, Holiday Park Multiservice Senior Center, Wheaton, MD, Oct 1995.

“Have You Put Away Your Sunscreen?”, Montgomery Gazette, Maryland, Sept. 1995.

“Treatment of Sun-Damaged Skin”, Montgomery Gazette, Maryland, Sept. 1995

CLINICAL STUDIES & RESEARCH ACTIVITIES

“Apremilast in Combination with Clobetasol Spray in the Treatment of Plaque Psoriasis of the Body with or without Scalp Involvement”. Investigator Initiated Study and Principal Investigator. Sponsored by Celgene Corp. 2018- Ongoing.

A 52-week multicenter, randomized, double-blind study of secukinumab to demonstrate efficacy as assessed by PASI and Investigator ‘s Global Assessment after 12 weeks of treatment, compared to ustekinumab, and to assess long-term safety, tolerability and efficacy in subjects with moderate to severe plaque psoriasis (CLARITY). Jan 2017-June 2018.

NPF-CORRONA Psoriasis Registry. Investigator. July 2015- Ongoing.

Glutathione Supplementation in Plaque Psoriasis, (Immunotec, Inc.). Principal Investigator. 2011.

Observe 5 safety surveillance study utilizing Etanercept to treat Psoriasis, (Amgen Inc.), October 2006-2011.

Gene Expression Analysis of Human Skin Samples, Before and After Systemic Treatment Intervention in Psoriasis, (Gene Logic Inc.). Principle Investigator. November 2003- April 2009.

Jet Trial: Juvederm Experience Trial. A Clinical Evaluation of Juvederm Ultra Injectable Gel for the Correction of Moderate to Severe Facial Wrinkles and Folds. (Allergan, Inc.), November 2006 - June 2007.

A Phase IV, Open label, multicenter prospective study to evaluate the safety and efficacy of the use of Solaraze Gel in the treatment of AK lesions post Cryosurgery (Doak Dermatologics) June 2006- November 2006.

Clobex spray community based research assessment trial to evaluate the efficacy, tolerance to treatment, and subject satisfaction with Clobex (clobetasol propionate) spray 0.05% as monotherapy or add-on therapy to existing systemic/topical agents in the treatment of moderate to severe plaque psoriasis. COBRA (Galderma Inc.) 2006.

Raptiva Epidemiologic study of Psoriasis outcomes and safety events in patients with chronic, moderate to severe plaque psoriasis. RESPONSE TRIAL (Genentech Inc.) 2005-2009.

A Phase IIIB, Open label, multicenter prospective study to evaluate the safety of subjects with Psoriasis treated with Etanercept [Enbrel] (Amgen Inc.) 2004.

A Phase IIIB, Open Label effectiveness and safety study of topical Imiquimod [Aldara] 5% cream in the treatment of Actinic Keratosis (3M Inc.) 2004.

A Phase IIIB, Open Label, multicenter study to evaluate the safety of subcutaneously administered Efalizumab [Raptiva] in moderate to severe Psoriasis (Genentech Inc.) 2003-2004.

Analysis of Gene Expression of Human Skin Samples through Disease Progression in Psoriasis (Gene Logic Inc.). Principle Investigator, 2002-2005.

Analysis of Gene Expression of Human Skin Samples through Gene Expression in Atopic Dermatitis (Gene Logic Inc.). Principle Investigator, 2003-2004.

A dose determination study comparing two different concentrations (0.3% and 1.0%) and two application frequencies of Clindamycin cream and its vehicle in the treatment of subjects with moderate to severe Rosacea (Dow Pharmaceuticals Inc.), 1999.

The safety and efficacy of Clindagel QD versus Vehicle QD in subjects with mild to moderate Acne Vulgaris (Galderma Inc.), 1999.

Phase I study of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer (Associate Investigator, National Institutes of Health), 1997.

Comparative effects of Fusidic acid (2%) lotion and Erythromycin (2%) solution in the treatment of acne vulgaris of the face (Leo Laboratories), Sept. 1994-Dec. 1994.

Double-blind randomized study to compare Lipocort C (clobetasol proprionate liposome cream 0.025%) versus clobetasol proprionate cream 0.05% in psoriasis (Lipopharm Inc.), 1993-94.

A multi-controlled double blind placebo controlled evaluation of topical 3% diclofenac in 2.5% hyaluronic acid in the treatment of superficial basal cell carcinoma (Hyal Pharmaceutical Corp.), June 1993-Dec. 1993.

Open study to compare EMLA patch versus EMLA 5% cream for analgesia prior to skin surgery (ASTRA Pharm. Inc.), June 1993-Dec.1993.

Double-blind randomized study to compare the efficacy of Famciclovir and Acyclovir versus Acyclovir alone in herpes zoster (Smith-Kline Beecham Inc.), Jan-June 1993.

Double-blind, randomized dose-ranging study to assess the efficacy of Famciclovir in genital herpes (Smith-Kline Beecham Pharma Inc.), Jan-June 1993.

Laboratory investigation of the immunogenic epitope(s) in Pemphigus Vulgaris, National Cancer Institute, N.I.H., July 1991-November 1992.

Clinical investigation of photodamaged skin treated with topical Ro 15-1570 (Hoffman-LaRoche, Inc.), McMaster University (Dermatology), Jan.-July 1989.

Clinical investigation of the protective effect of Vitamin E in the hemolysis associated with Dapsone treatment in patients with Dermatitis Herpetiformis, McMaster University (Dermatology & Hematology), Jan.-July 1989.

Laboratory investigation of genetic control of resistance and susceptibility to experimental cutaneous candidiasis in mice, Montreal General Hospital (Dermatology & Immunology), McGill University, Jan.-April 1987.

VOLUNTEER AND COMMUNITY SERVICE

Honorary Medical Walk Chair, Walk To Cure Psoriasis, Washington, D.C., September 2011.

Health Volunteers Overseas, Hospital Mexico, San Jose, Costa Rica, August 2010.

McGill Alumni Association, Leadership Council, Washington, D.C.

ACADEMIC/PROFESSIONAL AWARDS

- 2018 Winner of “Doctors Choice Award”. Top 100 doctor as voted by other doctors.
- 2017 “Voluntary Teacher of the Year” Award. Department of Dermatology.
George Washington University
- 2003-2017 “America’s Top Physicians”, Consumers’ Research Council of America
- 2015 “RK Schachter Lectureship” in Recognition of your contributions to the lives of
patients with psoriasis: University of Toronto
- 2013 “Super Doctors” Award
- 2011 Leadership Circle for Volunteerism, American Academy of Dermatology
- 2007-2017 “Best Dermatologist”, Washingtonian Magazine
- 1999-2016 “Top Doctors”, Washingtonian Magazine
- 1983 Scarlet Key, McGill University, Highest Distinction in Student Activities
- 1983 Muriel Roscoe Prize in Biology, McGill University
- 1980-83 J.W. McConnell Scholarship Award in Science, McGill University
- 1980-83 McGill University Scholar